Tenofovir Disoproxil Fumarate in the Clinical Practice: An Overview

Abstract

Tenofovir disoproxil fumarate (tenofovir DF) is the generic name of the chemical compound 9[R(2[[bis]]isopropoxycarbonyl) oxy]methoxy]phosphonyl]methoxy]propyl] adenine fumarate (1:1), the prodrug of tenofovir, the first nucleotide analogue reverse transcriptase inhibitor approved in October 2001 by the Food and Drugs Administration in USA and then, in February 2002, by the European Medicines Evaluation Agency in Europe for the treatment of